A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.